Recce Ltd has released a press release.
Ethics Approval for Phase I/II UTI Trial Expansion
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Ethics Approval to Start Phase I/II (I.V.) Clinical Trial
- New Family 4 Patent to be Granted for RECCE Anti-Infectives
- Recce Receives Further A$973,144 R&D Advance
- Corporate Presentation - WI Emergence 2023
- Recce Selects CMAX for Phase I/II UTI Clinical Trial
Later from Recce Pharmaceuticals
- First Cohort Dosed in Rapid Infusion Phase I/II UTI study
- A$801,604 R&D Rebate Advance Received
- Phase I Clinical Trial Data Review Complete
- Clarification - 5x Higher Concentration in Urine & Plasma
- Scientia Doses Ahead of Schedule in Phase I/II UTI Trial
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals